Navigation Links
Pneumococcal conjugate vaccines can improve the lives of HIV-infected children
Date:11/28/2007

An international team of experts has published the first comprehensive review of evidence on pneumococcal conjugate vaccination (PCV) for children with HIV infection. Now available in the on-line edition of the journal Lancet Infectious Diseases, the review shows that HIV increases the risk of pneumococcal infection by up to 40 fold, that the disease is usually due to serotypes in the PCV, and that the vaccine can protect HIV-infected infants. The authors conclude that PCV can improve the lives of HIV-infected children and should be considered a potentially valuable complement to existing treatment strategies for HIV-infected children (1).

In the run up to World AIDS Day (1st December 2007), the study authors are calling for action to make pneumococcal vaccines available for all children in resource-poor countries, especially those with a high burden of HIV infection.

Streptococcus pneumoniae, a bacterium that is a major cause of pneumonia, meningitis and blood stream infections, kills over 800,000 and up to one million children every year (2). Tragically children with HIV are at a vastly increased risk of getting pneumoccocal disease, due to their weakened immune system (3) (4).

The expert review, authored by seven leading experts in pneumococcal disease and HIV medicine, based in the US and Africa, summarises available data on the burden of pneumococcal disease and the safety and efficacy of pneumococcal vaccination in HIV infected children. The review found: (1)

  • HIV increased the risk of pneumococcal disease in HIV infected as compared with uninfected children (studies found it to be as high as 43-fold)
  • The serotypes, or strains, of the bacteria included in the currently licensed, and near-licensed vaccines, include the majority of the serotypes that cause invasive pneumococcal disease in HIV-infected children and adults
  • Pneumococcal conjugate vaccine protects against pneumonia and invasive pneumococcal disease when given to HIV infected infants

The review paper, "The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease", indicates that PCV should be considered an important complement to highly active antiretroviral therapy (HAART), which has brought marked improvements to morbidity and mortality in HIV-infected people. The study advocates for vaccination of all infants in areas with high rates of HIV infection.

Lead author Dr Sandra Bliss, a physician with Johns Hopkins School of Medicine said, this report gathers all the available data on the risks and benefits of PCV in HIV infected children. When viewed altogether, it makes a compelling case for action to vaccinate HIV infected children against pneumococcal disease.

Earlier this year, the World Health Organization recommended that all countries include pneumococcal conjugate vaccines in their routine immunization programs and that the highest priority be given to countries with high child mortality rates and/or a high HIV prevalence rate. Already more than 17 countries have national programs that include pneumococcal conjugate vaccines, and through support from the GAVI Alliance, children in the worlds poorest countries can begin accessing the vaccine as early as 2008.

Dr Keith Klugman, Professor of Global Health at Emory University, Atlanta, USA said, a simple intervention that can reduce the suffering, and improve the quality of life, of HIV infected children and adults is desperately needed in countries adversely affected by HIV. I welcome the introduction of the pneumococcal vaccine and am eager for the day it is routinely available for all children who need it.


'/>"/>

Contact: Caroline Tatum
ctatum@ruderfinn.co.uk
44-020-746-28957
GAVI's PneumoADIP
Source:Eurekalert

Related medicine news :

1. Wyeth Comments on PREVNAR and Trends in Pneumococcal Disease
2. Colorado Influenza and Pneumococcal Alert Coalition (CIPAC) Partners with Novartis Vaccines for Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers
3. Duramed Launches New Indication for ENJUVIA(TM) (Synthetic Conjugated Estrogens, B) at North American Menopause Society Annual Meeting
4. Human Papilloma Virus vaccines may decrease chances of oral cancer
5. CDC Study Links Thimerosal in Vaccines to Motor/Phonic Tics and Deficits in Attention, Behavior Control, Verbal IQ
6. Novartis Vaccines Launches National Gift-Giving Program to Help Protect Loved Ones by Reserving an Influenza Vaccination
7. Combination vaccines okay for infants, study shows
8. Novartis Vaccines Partners With RediClinic for Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers
9. Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers
10. St. Jude finds molecule that could improve cancer vaccines and therapy for other diseases
11. Study Shows Cholera Can be Controlled With Oral Vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... Sue Desmond-Hellmann, ... Class of 2016 to stretch the limits of human possibility in her keynote address ... p.m. in the Georgia Dome. , Drawing on her rich experience as a scientist, ...
(Date:5/3/2016)... ... , ... Calvary Hospital recently hosted a reception to mark a new music ... at Mary, Manning Walsh Home (MMW) in Manhattan. , During the school year, ... hour, once a week. The music brings a lot of joy to the patients, ...
(Date:5/3/2016)... NJ (PRWEB) , ... May 03, 2016 , ... ... BCBSNJ) today announced that it has been honored as one of the nation’s ... the 2016 InformationWeek Elite 100. Horizon received the recognition for technology achievements that ...
(Date:5/3/2016)... Springs, FL (PRWEB) , ... May 03, 2016 ... ... nation’s leading innovative specialty pharmacies, will be represented at the 2016 Asembia ... Las Vegas. The Asembia Summit is the largest U.S. health care conference for ...
(Date:5/3/2016)... ... May 03, 2016 , ... Empyrean ... launching a new client service center in La Vergne, Tennessee, near Nashville. The ... the full range of Empyrean client services. , “Our Nashville-area center allows us ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... , May 3, 2016 BioNovus ... Center,s Institute for Advancing Medical Innovation (IAMI) today ... new drugs, diagnostics and medical devices. ... Innovations with rights to license, develop and commercialize ... "This partnership represents a significant ...
(Date:5/3/2016)... Research and Markets has announced ... Therapy Market Outlook 2020" report to their offering. ... ,Recombinant technology has improved significantly in past years due ... in coming years. Many cancer drugs have been developed ... are also expected to be developed with its help. ...
(Date:5/3/2016)...  Axiogenesis has acquired a major investment from Sino-German High-Tech Fund to further expand product development, strengthen its disease ... ... ... ... ...
Breaking Medicine Technology: